Insulin glargine new formulation HOE901
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type1 Diabetes
Conditions
Type1 Diabetes
Trial Timeline
Apr 1, 2013 → Aug 1, 2013
NCT ID
NCT01838083About Insulin glargine new formulation HOE901
Insulin glargine new formulation HOE901 is a phase 1 stage product being developed by Sanofi for Type1 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT01838083. Target conditions include Type1 Diabetes.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01838083 | Phase 1 | Completed |
Competing Products
11 competing products in Type1 Diabetes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose | Precigen | Phase 1/2 | 36 |
| Insulin Lispro | Eli Lilly | Phase 1 | 33 |
| LY900014 + Insulin Lispro | Eli Lilly | Phase 2 | 52 |
| Selumetinib | AstraZeneca | Pre-clinical | 23 |
| Dapagliflozin + Placebo Oral Tablet | AstraZeneca | Phase 1 | 33 |
| Semaglutide Pen Injector + Placebo | Novo Nordisk | Phase 2 | 51 |
| Aspart | Novo Nordisk | Approved | 84 |
| Insulin glulisine (U300) + Insulin glulisine + Insulin aspart + NPH insulin + Glucagon + Glucose + Heparin | Sanofi | Phase 1 | 32 |
| verapamil 120mg tablet + placebo | Dexcom | Phase 3 | 74 |
| UP421 | Sana Biotechnology | Phase 1 | 28 |
| XeriSol glucagon | Xeris Pharmaceuticals | Phase 1 | 28 |